Inhibikase Therapeutics Announces Dosing of First Parkinson’s Patient in Its Phase Ib Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc. announced dosing of the first Parkinson’s patient in its Phase Ib clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.